|
|
Comparative review of 4 popular penis stretching devices --
CLICK HERE
|
SizeGenetics System
[ Order ]
|
|
Penile
enlargement without surgery with the SizeGenetics
Device
Scientific Research presented in
the 1st Virtual Sexology and Hispanoamerican Sexual Education Congress
(February -2001) Dr. Eduardo A. Gomez de Diego „ 1998 Andrology
Services ,Andromedical Clinic, Madrid (Spain)
1.
Introduction:
When the human
tissues are submitted to a force of traction, they react by increasing in
size.
The principle of traction is applied in modern medicine, for
the generation of new tissue to cover burn wounds or areas of hair loss (
placing a tissular expander underneath the normal skin ) or for the
lengthening of bones.
In other cultures this principle is applied
to lengthen different parts of the body like the Giraffe Women of the
Paduang tribe in Birmania ; or the lengthening of the lips in certain
African tribes of Africa that use wood to create traction; and in India
where they hang stones on the penis of men as a form of penitence with the
resulting enlargement of the organ.
Based on this principle of
external traction the SizeGenetics was designed . It is able to
exhort a gradual traction force of 600 to 1500 grams.
The device
consists of a plastic ring, where the penis is introduced and from where 2
dynamic metalic rods that originate the traction. In the superior part
there is a plastic support where a silicone band holds the glans in
place.
Based on our clinical
experience the traction device yields the following results:
- An increase in the length of the penis in erection and
flaccidity.
- An increase in the perimeter of the penis in erection and
flaccidity.
- This results will be analyzed statistically to be verified and
quantified
[ Go To SizeGenetics Website ]
2.
Materials and Methods
Number of
patients: 37 patients, ages between 22 and 60 years of age. These
men proceed from different cities in Spain.
Selection
of patients: patients included were healthy men with normal
erection capabilities and without penile surgeries. Patients with penile
or other diseases where excluded from the studies.
Traction device: The SizeGenetics®, German penile traction
device.
Traction
Force: 600 gr during 1st month, 900 gr during 2nd month, 1100 gr
durante 3th and 4th mes, and 1200 gr during 5th y 6th month.
Usage period: 10 hours a day, during every day of
the month for a period of 3-6 months.
[ Go To SizeGenetics Website ]
3. Results
3.1.- INCREASE IN LENGTH IN ERECTION:
The average increase in the length of the penis in erection
by month is of 0.4726 cm. The standard deviation is of 0.1329 cm. The
confidential interval of 95% is of [0.4283 ; 0.5169] which indicates a
minimal gain in the population of 0.4283 cm/month.
Regression line is:
DL erec = - 0.327 + 0.562 x
t
This calculation will allow us to estimate the increase in length
of the penis in erection, based on the months of use of the device. There
is a 57.7% variance in the increment in longitude, which is explained by
the variance in the duration of treatment ( R2= 0.577 ). The other 42.3%
is due to other differences innate to each individual and not relative to
the duration of the treatment
[ Go To SizeGenetics Website ]
3.2.- INCREMENT IN LENGTH IN THE FLACCID STATE
The increment in length in the flaccid state is relative to
the time of usage of the device. Such an increment is linear as shown in
the graph. The longer the device is used, the greater the increase in
length. The coefficient of the linear correlation between the time of
usage and the increment in longitude in the flaccid state is of 0.725 (
p=0.000 ).
The average monthly increment in longitude of the penis in
the flaccid state is 0.4834 cm and the typical deviation is 0.1983 cm. The
confidence interval of 95% is of [0.4173 ; 0.5495] and indicates a minimum
increase in the population of 0.4173 cm/month.
Regression line is:
DL flac = - 1.300 + 0.840 x
t
This calculation allows us to estimate the increment in longitude
in the flaccid state based on the months in which the device is used.
There is a 52.5% variance in the increment in longitud which is explained
by the variance of the duration of treatment ( R2= 0.525 ). The other
47.5% is due to other differences innates to the individual and not
relative to the duration of the treatment.
[ Go To SizeGenetics Website ]
3.3.- VARIABILITY:
The variability in the increment in longitude in erection
is different from that of flaccidity, being the difference in variance
significant ( p= 0.003 ) which indicates a greater dispersion of the
increases in length during flaccidity than in erection.
3.4.- THE INCREMENT IN LONGITUDE DOES NOT DEPEND ON
THE AGE:
A very interesting result was that the increment in
longitude does not depend on the age of the patient, since the coefficient
of the linear correlation is not significant ( r=0.008, p=0.961). In other
words, the age of the patient does not effect the increment in longitude.
-
-
-
-
[ Go To SizeGenetics Website ]
3.7.- LONGITUDE INCREASE IN ERECTION STATE DEPENDING ON
USE:
Dividing the population studied in four sub groups
depending on the usage time of the SizeGenetics®. we obtain the following
results.
Three months usage: The median
longitude increment in erection state was 1.4118, obtaining a median
growth of 10.5580% over the initial longitude. The confidence interval of
95% of the studied population was ( 1.1522; 1.6713) which shows a median
minimal growth of 1.1522 cm in three months.
Four months
usage: The median longitude increment in erection state was
1.8462, obtaining a median growth of 14.1113% over the initial longitude.
The confidence interval of 95% of the studied population was(1.5809;
2.1114) which shows a median minimal growth of 1.5809 cm in four months.
Five months usage: The median
longitude increment in erection state was 2.2750, obtaining a median
growth of 16.6303% over the initial longitude. The confidence interval of
95% of the population studied was (1.7656; 2.7844) which shows a median
minimal growth of 1.7656 cm in four months.
Six months
usage: The median longitude increment in erection state was
3.3333, obtaining a median growth of 27.5% over the initial longitude. The
confidential interval of 95% of the population studied was (2.8162;
3.8504) which shows a median minimal growth of 2.8162 cm in six
months. The samples corresponding to five and six months are very small
which makes small intervals and less reliable.
3.8.- DISTRIBUTION:
Although the variables considered in the population are not
normal, the median samples, have normal distribution since the amount of
the sample is greater than 20.
3.9.- ABBREVIATIONS:
|
Inc-Long-Erec |
Longitude increment in erection
state |
|
DL
erec |
Change in Longitude increment in
erection state |
|
I.L.ERT |
Longitude increment in erection
as a function of the time variable |
|
I.L.FLAC |
Longitude increment in flaccid
state |
|
DL
flac |
Change in Longitude increment in
flaccid state |
|
I.L.FLT |
Longitude increment in flaccid
state in function of time |
|
Inc-Long-Erec |
Longitude increment in erection
state |
|
% I
Long-Erec |
Longitude increment percentage
in erection
state. |
[ Go To SizeGenetics Website ]
4.
Conclusions
The use of the German traction device (SizeGenetics® ) will increase the length of
the penis, both in the erectile and flaccid state.
The increase in length, both in and flaccidity, is directly
proportional to the time of use.
The increase in length both in erection and flaccidity,
does not depend on the natural size of the patient.
The average growth in length of the penis in cm/month in
95% of the patients was between 0.4283 and 0.5163 in erection, and between
0.4173 and 0.5495 in flaccidity.
The increments of change in length of the penis in erection
are more uniform than those in flaccidity which tend to be more disparate
.
The increment of change in the length of the penis in
erection is not relative to the age of the patient.
The use of the penile traction device will increase the
perimeter of the penis, both in erection and flaccidity.
The average growth in perimeter in cm/month in 95% of the
patients was between 0.6111 and 1.0200 in erection, and between 0.6386 and
1.0425 in flaccidity. Treatment was 3-6 months duration.
-
[ Go To SizeGenetics Website ]
5.
Anex
PATIENT RESULTS (Using the SizeGenetics®):
| Nombre
|
Edad |
Inicio |
L-Erec1 |
L-Flac1 |
P-Erec1 |
P-Flac1 |
Meses |
L-Erec2 |
L-Flac2 |
P-Erec2 |
P-Flac2 |
| LAA |
60 |
15.1.98
|
12.0 |
8.0 |
12.0 |
10.0 |
3.0 |
13.5 |
9.0 |
13.5 |
10.5
|
| EAG |
37 |
30.1.98
|
14.5 |
8.0 |
12.0 |
8.5 |
4.0 |
16.5 |
9.5 |
13.0 |
10.5
|
| VA |
27 |
26.11.97
|
16.3 |
10.4 |
13.9 |
10.1 |
3.0 |
17.8 |
12.5 |
14.5 |
11.5
|
| EAA |
46 |
15.3.98
|
14.5 |
10.5 |
12.0 |
10.0 |
6.0 |
17.6 |
15.7 |
13.2 |
11.2
|
| JBV |
25 |
27.3.98
|
15.0 |
8.0
13.0 |
9.0 |
3.0 |
16.6 |
9.5 |
13.3 |
10.5
|
| ABB |
39 |
29.6.98
|
14.0 |
11.0 |
13.0 |
11.0 |
3.0 |
15.5 |
12.5 |
14.0 |
12.0
|
| CBG |
37 |
19.1.98
|
12.5 |
6.0 |
12.0 |
9.0 |
4.0 |
14.0 |
8.8 |
12.5 |
9.4
|
| JBL |
25 |
7.5.98
|
13.7 |
9.0 |
11.5 |
10.0 |
4.0 |
16.3 |
11.5 |
13.5 |
12.0
|
| JCB |
27 |
19.11.97
|
13.0 |
8.0 |
14.5 |
12.0 |
6.0 |
16.4 |
11.1 |
14.2 |
12.2
|
| JJCA |
33 |
1.6.98
|
10.5 |
4.9 |
11.0 |
9.5 |
3.0 |
12.0 |
5.5 |
11.5 |
9.5
|
| JCA |
32 |
4.2.98
|
14.0 |
10.0 |
10.0 |
9.0 |
4.0 |
15.9 |
12.0 |
12.2 |
10.5
|
| ODV |
25 |
4.3.98
|
16.5 |
9.5 |
13.0 |
9.7 |
3.0 |
18.0 |
11.0 |
13.3 |
10.0
|
| PDS |
22 |
10.6.98
|
14.4 |
8.3 |
11.0 |
7.8 |
3.0 |
15.8 |
9.0 |
11.6 |
8.3
|
| AGM |
41 |
26.11.98
|
13.0 |
9.0 |
11.0 |
10.0 |
4.0 |
15.0 |
9.5 |
11.0 |
10.0
|
| MGF |
32 |
29.9.97
|
12.5 |
5.5 |
12.5 |
10.0 |
4.0 |
14.5 |
8.0 |
13.0 |
10.0
|
| AHM |
44 |
5.3.98
|
11.5 |
8.0 |
13.0 |
12.0 |
3.0 |
13.0 |
9.5 |
14.0 |
12.0
|
| AAMP |
37 |
12.3.98
|
12.7 |
7.0 |
10.5 |
7.5 |
3.0 |
14.0 |
9.0 |
11.0 |
9.0
|
| JLMO |
34 |
30.1.98
|
14.8 |
11.0 |
11.0 |
9.3 |
4.0 |
15.8 |
11.0 |
12.7 |
9.3
|
| JAMV |
41 |
28.7.97
|
17.0 |
10.0 |
14.0 |
12.5 |
5.0 |
19.6 |
12.3 |
15.0 |
13.5
|
| FOR |
8% |
9.11.97
|
12.5 |
7.0 |
10.0 |
9.0 |
5.0 |
14.5 |
11.0 |
11.0 |
10.5
|
| ROM |
28 |
12.11.97
|
16.0 |
8.5 |
13.0 |
9.0 |
5.0 |
18.0 |
12.5 |
13.5 |
10.5
|
| JPC |
33 |
16.1.98
|
13.7 |
7.2 |
12.3 |
10.1 |
3.0 |
16.7 |
8.7 |
13.1 |
10.9
|
| JAPG |
29 |
4.11.97
|
10.0 |
8.0 |
12.0 |
10.0 |
6.0 |
13.5 |
11.5 |
13.0 |
11.0
|
| FPR |
8% |
20.3.98
|
10.5 |
7.0 |
12.0 |
10.0 |
3.0 |
11.3 |
7.3 |
12.7 |
10.0
|
| JPF |
42 |
23.3.98
|
13.0 |
7.0 |
13.0 |
10.0 |
3.0 |
14.5 |
8.5 |
13.0 |
10.5
|
| AJRF |
26 |
28.11.97
|
14.0 |
9.0 |
13.0 |
9.0 |
4.0 |
16.0 |
10.7 |
13.0 |
10.0
|
| ARR |
58 |
7.10.97
|
11.0 |
7.0 |
11.0 |
9.0 |
3.0 |
12.0 |
8.0 |
12.0 |
10.0
|
| RRG |
25 |
25.11.97
|
14.5 |
11.0 |
11.0 |
10.0 |
3.0 |
15.0 |
12.4 |
11.7 |
10.8
|
| CSM |
35 |
24.2.98
|
15.0 |
9.0 |
11.0 |
9.0 |
3.0 |
16.5 |
11.0 |
12.0 |
10.0
|
| ASE |
35 |
20.3.98
|
12.5 |
7.5 |
11.5 |
9.0 |
4.0 |
14.5 |
9.5 |
12.5 |
10.5
|
| ASPA |
42 |
7.11.97
|
14.0 |
7.5 |
12.0 |
9.0 |
4.0 |
16.0 |
9.5 |
13.0 |
10.5
|
| SSF |
27 |
15.8.97
|
14.5 |
7.0 |
14.5 |
8.0 |
3.0 |
15.9 |
8.0 |
15.0 |
8.7
|
| ISB |
22 |
23.9.97
|
11.5 |
7.5 |
11.0 |
9.5 |
4.0 |
13.5 |
10.2 |
11.3 |
10.3
|
| FT |
53 |
19.11.97
|
14.5 |
10.0 |
13.0 |
10.0 |
3.0 |
16.0 |
11.5 |
13.5 |
10.5
|
| EVC |
24 |
29.12.97
|
11.0 |
7.0 |
11.5 |
9.0 |
5.0 |
13.5 |
9.0 |
12.5 |
10.5
|
| PV |
33 |
8.10.97
|
12.0 |
8.5 |
15.5 |
13.0 |
4.0 |
13.0 |
9.5 |
16.0 |
13.0
|
| JSVS |
32 |
24.1.98
|
12.0 |
6.0 |
10.5 |
9.0 |
4.0 |
14.0 |
8.5 |
12.5 |
9.5
|
L-Erec1 =
Length in Erection initial L-Flac1 = Length in Flaccidity
inicial P-Erec1 = Perimeter in Erection initial P-Flac1
= Perimeter in Flaccidity inicial L-Erec2 = Length in
Erection final L-Flac2 = Length in Flaccidity
final P-Erec2 = Perimeter in Erection final P-Flac2 =
Perimeter in Flaccidity final
|